AEMD: Aethlon enters Cohort 3 of Australian Hemopurifier oncology study; posts FY2026 results

AI Summary

Aethlon (AEMD) advanced its Australian Hemopurifier oncology study into the third and final dosing cohort, treated the first Cohort 3 participant with three Hemopurifier sessions without device deficiencies, and reported an independent DSMB found no safety concerns after Cohort 2. The company also expanded Hemopurifier IP (U.S./EU patents for COVID/Long COVID), continued preclinical EV work in RA and CKD, and reported FY2026 results: ~$5.0M cash at year-end (plus ~$1.85M raised post-period), operating expenses down 21.9% to ~$7.3M, and a net loss of ~$7.2M.

Positives

Entered Cohort 3 of Australian oncology trial and treated first participant with three Hemopurifier sessions without device deficiencies or immediate complications
Independent DSMB reviewed Cohort 2 data, identified no safety concerns, and recommended advancing to Cohort 3
Strengthened balance sheet post-period with ~ $1.85M raised and reported ~$5.0M cash at March 31, 2026

Negatives

Cash on hand (~$5.0M plus ~$1.85M raised post-period) may be limited and company warns additional financing could be needed
Oncology study is an early feasibility trial (9–18 patients), so clinical signals will be preliminary and limited
Reported FY2026 net loss of ~$7.2M, indicating continued reliance on external capital